Cytokinetics, Incorporated (CYTK)
USD 37.35
(-12.98%)
USD 37.35
(-12.98%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 7.53 Million USD | -92.04% |
| 2022 | 94.58 Million USD | 34.3% |
| 2021 | 70.42 Million USD | 26.15% |
| 2020 | 55.82 Million USD | 107.79% |
| 2019 | 26.86 Million USD | -14.71% |
| 2018 | 31.5 Million USD | 135.64% |
| 2017 | 13.36 Million USD | -87.44% |
| 2016 | 106.4 Million USD | 271.3% |
| 2015 | 28.65 Million USD | -38.95% |
| 2014 | 46.94 Million USD | 53.16% |
| 2013 | 30.64 Million USD | 305.45% |
| 2012 | 7.55 Million USD | 88.98% |
| 2011 | 4 Million USD | 55.22% |
| 2010 | 2.57 Million USD | -96.84% |
| 2009 | 81.53 Million USD | 556.51% |
| 2008 | 12.42 Million USD | -8.82% |
| 2007 | 13.62 Million USD | 335.63% |
| 2006 | 3.12 Million USD | -64.91% |
| 2005 | 8.91 Million USD | -33.7% |
| 2004 | 13.44 Million USD | 27.09% |
| 2003 | 10.57 Million USD | -7.19% |
| 2002 | 11.39 Million USD | 34.61% |
| 2001 | 8.46 Million USD | 0.0% |
| 2000 | - USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 835 Thousand USD | -50.06% |
| 2024 Q2 | 249 Thousand USD | -70.18% |
| 2023 Q2 | 867 Thousand USD | -81.21% |
| 2023 Q1 | 4.61 Million USD | 135.72% |
| 2023 Q4 | 1.67 Million USD | 342.33% |
| 2023 FY | 7.53 Million USD | -92.04% |
| 2023 Q3 | 378 Thousand USD | -56.4% |
| 2022 Q3 | 2.51 Million USD | -97.17% |
| 2022 Q4 | 1.95 Million USD | -22.19% |
| 2022 Q1 | 1.14 Million USD | -97.94% |
| 2022 FY | 94.58 Million USD | 34.3% |
| 2022 Q2 | 88.96 Million USD | 7649.83% |
| 2021 Q2 | 2.84 Million USD | -56.58% |
| 2021 Q3 | 5.43 Million USD | 91.24% |
| 2021 Q4 | 55.6 Million USD | 922.62% |
| 2021 FY | 70.42 Million USD | 26.15% |
| 2021 Q1 | 6.54 Million USD | -2.59% |
| 2020 Q2 | 3.59 Million USD | -6.07% |
| 2020 Q3 | 41.68 Million USD | 1060.26% |
| 2020 FY | 55.82 Million USD | 107.79% |
| 2020 Q4 | 6.72 Million USD | -83.88% |
| 2020 Q1 | 3.82 Million USD | -26.61% |
| 2019 Q4 | 5.21 Million USD | -13.92% |
| 2019 Q1 | 8.46 Million USD | -9.74% |
| 2019 FY | 26.86 Million USD | -14.71% |
| 2019 Q2 | 7.13 Million USD | -15.68% |
| 2019 Q3 | 6.05 Million USD | -15.16% |
| 2018 Q1 | 5.26 Million USD | 29366.67% |
| 2018 Q2 | 6.21 Million USD | 17.98% |
| 2018 Q3 | 10.64 Million USD | 71.21% |
| 2018 Q4 | 9.37 Million USD | -11.88% |
| 2018 FY | 31.5 Million USD | 135.64% |
| 2017 Q2 | 3.05 Million USD | -26.49% |
| 2017 FY | 13.36 Million USD | -87.44% |
| 2017 Q3 | 6.18 Million USD | 102.42% |
| 2017 Q1 | 4.15 Million USD | -87.47% |
| 2017 Q4 | -18 Thousand USD | -100.29% |
| 2016 Q2 | 5.8 Million USD | -31.1% |
| 2016 Q1 | 8.42 Million USD | -13.69% |
| 2016 FY | 106.4 Million USD | 271.3% |
| 2016 Q3 | 59.04 Million USD | 917.7% |
| 2016 Q4 | 33.13 Million USD | -43.88% |
| 2015 Q4 | 9.75 Million USD | 22.81% |
| 2015 FY | 28.65 Million USD | -38.95% |
| 2015 Q3 | 7.94 Million USD | 21.45% |
| 2015 Q2 | 6.54 Million USD | 48.21% |
| 2015 Q1 | 4.41 Million USD | -79.71% |
| 2014 Q3 | 9.41 Million USD | 20.89% |
| 2014 Q4 | 21.75 Million USD | 131.1% |
| 2014 Q1 | 7.97 Million USD | -67.23% |
| 2014 FY | 46.94 Million USD | 53.16% |
| 2014 Q2 | 7.78 Million USD | -2.39% |
| 2013 Q3 | 4.46 Million USD | 342.91% |
| 2013 FY | 30.64 Million USD | 305.45% |
| 2013 Q4 | 24.34 Million USD | 444.84% |
| 2013 Q2 | 1 Million USD | 22.9% |
| 2013 Q1 | 821 Thousand USD | -62.41% |
| 2012 Q3 | 1.71 Million USD | -6.9% |
| 2012 Q4 | 2.18 Million USD | 27.42% |
| 2012 FY | 7.55 Million USD | 88.98% |
| 2012 Q1 | 1.82 Million USD | 140.42% |
| 2012 Q2 | 1.84 Million USD | 1.15% |
| 2011 Q1 | 763 Thousand USD | -30.57% |
| 2011 Q2 | 1.05 Million USD | 38.01% |
| 2011 Q3 | 1.42 Million USD | 35.52% |
| 2011 Q4 | 757 Thousand USD | -46.95% |
| 2011 FY | 4 Million USD | 55.22% |
| 2010 Q4 | 1.09 Million USD | 178.93% |
| 2010 FY | 2.57 Million USD | -96.84% |
| 2010 Q1 | 621 Thousand USD | -39.3% |
| 2010 Q2 | 462 Thousand USD | -25.6% |
| 2010 Q3 | 394 Thousand USD | -14.72% |
| 2009 Q3 | 5.5 Million USD | -92.35% |
| 2009 Q4 | 1.02 Million USD | -81.42% |
| 2009 FY | 81.53 Million USD | 556.51% |
| 2009 Q1 | 3.07 Million USD | -2.35% |
| 2009 Q2 | 71.93 Million USD | 2236.91% |
| 2008 Q3 | 3.12 Million USD | 1.66% |
| 2008 Q1 | 3.06 Million USD | -1.32% |
| 2008 FY | 12.42 Million USD | -8.82% |
| 2008 Q4 | 3.15 Million USD | 0.86% |
| 2008 Q2 | 3.07 Million USD | 0.16% |
| 2007 FY | 13.62 Million USD | 335.63% |
| 2007 Q4 | 3.11 Million USD | -24.7% |
| 2007 Q3 | 4.13 Million USD | 30.0% |
| 2007 Q2 | 3.17 Million USD | -0.87% |
| 2007 Q1 | 3.2 Million USD | 1967.74% |
| 2006 Q1 | 1.42 Million USD | -33.77% |
| 2006 Q3 | 106 Thousand USD | -92.67% |
| 2006 Q4 | 155 Thousand USD | 46.23% |
| 2006 FY | 3.12 Million USD | -64.91% |
| 2006 Q2 | 1.44 Million USD | 1.83% |
| 2005 Q2 | 2.34 Million USD | -8.98% |
| 2005 Q3 | 1.85 Million USD | -20.76% |
| 2005 FY | 8.91 Million USD | -33.7% |
| 2005 Q4 | 2.14 Million USD | 15.58% |
| 2005 Q1 | 2.57 Million USD | 15.54% |
| 2004 Q2 | 2.9 Million USD | -50.57% |
| 2004 Q3 | 2.44 Million USD | -15.55% |
| 2004 Q1 | 5.86 Million USD | 121.9% |
| 2004 Q4 | 2.22 Million USD | -9.11% |
| 2004 FY | 13.44 Million USD | 27.09% |
| 2003 Q1 | 2.74 Million USD | 0.0% |
| 2003 FY | 10.57 Million USD | -7.19% |
| 2003 Q4 | 2.64 Million USD | 0.0% |
| 2003 Q3 | 2.64 Million USD | 3.52% |
| 2003 Q2 | 2.55 Million USD | -7.09% |
| 2002 FY | 11.39 Million USD | 34.61% |
| 2001 FY | 8.46 Million USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Sangamo Therapeutics, Inc. | 176.23 Million USD | 95.727% |
| IDEAYA Biosciences, Inc. | 23.38 Million USD | 67.8% |
| Eton Pharmaceuticals, Inc. | 31.64 Million USD | 76.203% |
| Autolus Therapeutics plc | 1.69 Million USD | -343.463% |
| Greenwich LifeSciences, Inc. | - USD | -Infinity% |
| Enlivex Therapeutics Ltd. | - USD | -Infinity% |
| Shattuck Labs, Inc. | 1.65 Million USD | -354.436% |
| LENZ Therapeutics, Inc. | - USD | -Infinity% |
| CervoMed Inc. | 7.14 Million USD | -5.39% |
| Rocket Pharmaceuticals, Inc. | - USD | -Infinity% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Aptose Biosciences Inc. | - USD | -Infinity% |
| Precision BioSciences, Inc. | 48.72 Million USD | 84.547% |
| Dyadic International, Inc. | 2.89 Million USD | -159.762% |
| TScan Therapeutics, Inc. | 21.04 Million USD | 64.226% |
| Intensity Therapeutics, Inc. | - USD | -Infinity% |
| Nektar Therapeutics | 90.12 Million USD | 91.645% |
| CytomX Therapeutics, Inc. | 101.21 Million USD | 92.56% |
| VYNE Therapeutics Inc. | 424 Thousand USD | -1675.943% |
| EyePoint Pharmaceuticals, Inc. | 46.01 Million USD | 83.637% |
| Leap Therapeutics, Inc. | - USD | -Infinity% |
| Adaptive Biotechnologies Corporation | 170.27 Million USD | 95.578% |
| GRI Bio, Inc. | 21.76 Million USD | 65.406% |
| Xenetic Biosciences, Inc. | 2.53 Million USD | -196.458% |
| Tenaya Therapeutics, Inc. | - USD | -Infinity% |
| NeuroSense Therapeutics Ltd. | - USD | -Infinity% |
| Psyence Biomedical Ltd. | - USD | -Infinity% |
| IGM Biosciences, Inc. | 2.13 Million USD | -253.521% |
| INmune Bio, Inc. | 155 Thousand USD | -4758.065% |
| Opthea Limited | 261.85 Thousand USD | -2775.593% |
| Milestone Pharmaceuticals Inc. | 1 Million USD | -653.0% |
| Omega Therapeutics, Inc. | 3.09 Million USD | -143.374% |
| Verastem, Inc. | - USD | -Infinity% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -115.143% |
| Pliant Therapeutics, Inc. | 1.58 Million USD | -376.582% |
| Tonix Pharmaceuticals Holding Corp. | 7.76 Million USD | 3.064% |
| Ligand Pharmaceuticals Incorporated | 131.31 Million USD | 94.266% |
| NextCure, Inc. | - USD | -Infinity% |
| Inhibikase Therapeutics, Inc. | 260.5 Thousand USD | -2790.595% |
| Organovo Holdings, Inc. | 109 Thousand USD | -6808.257% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| Arvinas, Inc. | 78.5 Million USD | 90.408% |
| Ovid Therapeutics Inc. | 391.69 Thousand USD | -1822.414% |
| CASI Pharmaceuticals, Inc. | 33.87 Million USD | 77.774% |
| Rani Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Centessa Pharmaceuticals plc | 6.85 Million USD | -9.879% |
| Arcturus Therapeutics Holdings Inc. | 157.74 Million USD | 95.227% |
| Syros Pharmaceuticals, Inc. | 9.93 Million USD | 24.215% |
| Senti Biosciences, Inc. | 2.56 Million USD | -194.026% |
| BioRestorative Therapies, Inc. | 145.8 Thousand USD | -5064.609% |
| Apollomics, Inc. | 821 Thousand USD | -817.174% |
| PureTech Health plc | 3.33 Million USD | -126.126% |
| Oncternal Therapeutics, Inc. | 785 Thousand USD | -859.236% |
| Barinthus Biotherapeutics plc | 802 Thousand USD | -838.903% |
| Kymera Therapeutics, Inc. | 78.59 Million USD | 90.419% |
| Synaptogenix, Inc. | - USD | -Infinity% |
| ChromaDex Corporation | 83.57 Million USD | 90.99% |
| Beam Therapeutics Inc. | 377.7 Million USD | 98.006% |
| Monopar Therapeutics Inc. | - USD | -Infinity% |
| Akebia Therapeutics, Inc. | 194.62 Million USD | 96.131% |
| Nurix Therapeutics, Inc. | 76.98 Million USD | 90.219% |
| Apellis Pharmaceuticals, Inc. | 396.59 Million USD | 98.101% |
| Dermata Therapeutics, Inc. | - USD | -Infinity% |
| Gritstone bio, Inc. | 1.33 Million USD | -465.74% |
| Mesoblast Limited | 5.9 Million USD | -27.584% |
| Virpax Pharmaceuticals, Inc. | - USD | -Infinity% |
| Xeris Biopharma Holdings, Inc. | 163.91 Million USD | 95.406% |
| Fate Therapeutics, Inc. | 63.53 Million USD | 88.148% |
| MediWound Ltd. | 18.68 Million USD | 59.702% |
| BioXcel Therapeutics, Inc. | 1.38 Million USD | -445.652% |
| Fortress Biotech, Inc. | 84.51 Million USD | 91.09% |
| Fractyl Health, Inc. Common Stock | 120 Thousand USD | -6175.0% |
| Achilles Therapeutics plc | - USD | -Infinity% |
| Seres Therapeutics, Inc. | 126.32 Million USD | 94.039% |
| Checkpoint Therapeutics, Inc. | 103 Thousand USD | -7210.68% |
| Atossa Therapeutics, Inc. | - USD | -Infinity% |
| Zai Lab Limited | 266.71 Million USD | 97.177% |
| Fresh Tracks Therapeutics, Inc. | 8 Million USD | 5.946% |
| Lyell Immunopharma, Inc. | 130 Thousand USD | -5692.308% |
| Vanda Pharmaceuticals Inc. | 192.64 Million USD | 96.091% |
| Tarsus Pharmaceuticals, Inc. | 17.44 Million USD | 56.841% |
| InMed Pharmaceuticals Inc. | 4.59 Million USD | -63.776% |
| FibroGen, Inc. | 147.75 Million USD | 94.904% |
| Celcuity Inc. | - USD | -Infinity% |
| SeaStar Medical Holding Corporation | - USD | -Infinity% |
| ContextLogic Inc. | 287 Million USD | 97.376% |
| GH Research PLC | - USD | -Infinity% |
| HOOKIPA Pharma Inc. | 20.12 Million USD | 62.591% |
| Cyclacel Pharmaceuticals, Inc. | 420 Thousand USD | -1692.857% |
| ImmuCell Corporation | 17.47 Million USD | 56.902% |
| Amylyx Pharmaceuticals, Inc. | 380.78 Million USD | 98.023% |
| Amarin Corporation plc | 306.91 Million USD | 97.547% |
| TG Therapeutics, Inc. | 233.66 Million USD | 96.777% |
| Aptevo Therapeutics Inc. | - USD | -Infinity% |
| Jasper Therapeutics, Inc. | - USD | -Infinity% |
| Foghorn Therapeutics Inc. | 34.15 Million USD | 77.953% |
| Y-mAbs Therapeutics, Inc. | 84.81 Million USD | 91.122% |
| Aptorum Group Limited | 431.37 Thousand USD | -1645.569% |
| Ultragenyx Pharmaceutical Inc. | 434.24 Million USD | 98.266% |
| BioCryst Pharmaceuticals, Inc. | 331.41 Million USD | 97.728% |
| Chemomab Therapeutics Ltd. | - USD | -Infinity% |
| Arrowhead Pharmaceuticals, Inc. | 240.73 Million USD | 96.872% |
| TransCode Therapeutics, Inc. | - USD | -Infinity% |
| RAPT Therapeutics, Inc. | - USD | -Infinity% |
| Ardelyx, Inc. | 124.45 Million USD | 93.95% |
| Ainos, Inc. | 122.11 Thousand USD | -6066.47% |
| Lyra Therapeutics, Inc. | 1.55 Million USD | -383.312% |
| Prothena Corporation plc | 91.37 Million USD | 91.759% |
| HilleVax, Inc. | - USD | -Infinity% |
| Adaptimmune Therapeutics plc | 60.28 Million USD | 87.509% |
| Celularity Inc. | 22.77 Million USD | 66.932% |
| Rallybio Corporation | - USD | -Infinity% |
| Cue Biopharma, Inc. | 5.49 Million USD | -37.158% |
| Omeros Corporation | - USD | -Infinity% |
| Humacyte, Inc. | - USD | -Infinity% |
| Immunocore Holdings plc | 249.42 Million USD | 96.981% |
| Cocrystal Pharma, Inc. | - USD | -Infinity% |
| Blueprint Medicines Corporation | 249.38 Million USD | 96.981% |
| IO Biotech, Inc. | - USD | -Infinity% |
| MEI Pharma, Inc. | 65.29 Million USD | 88.468% |
| GT Biopharma, Inc. | - USD | -Infinity% |
| Cabaletta Bio, Inc. | - USD | -Infinity% |
| Summit Therapeutics Inc. | - USD | -Infinity% |
| Alaunos Therapeutics, Inc. | 5000.00 USD | -150500.0% |
| Marinus Pharmaceuticals, Inc. | 30.98 Million USD | 75.701% |
| Scholar Rock Holding Corporation | - USD | -Infinity% |
| Pulmatrix, Inc. | 7.29 Million USD | -3.179% |
| Elicio Therapeutics, Inc. | - USD | -Infinity% |
| X4 Pharmaceuticals, Inc. | - USD | -Infinity% |
| Vigil Neuroscience, Inc. | - USD | -Infinity% |
| Acelyrin, Inc. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | 79.242% |
| Vor Biopharma Inc. | - USD | -Infinity% |
| Evogene Ltd. | 5.64 Million USD | -33.511% |
| Replimune Group, Inc. | - USD | -Infinity% |
| Applied Therapeutics, Inc. | 9.99 Million USD | 24.647% |
| PDS Biotechnology Corporation | - USD | -Infinity% |
| Hoth Therapeutics, Inc. | - USD | -Infinity% |
| BridgeBio Pharma, Inc. | 9.3 Million USD | 19.058% |
| AEON Biopharma, Inc. | - USD | -Infinity% |
| BioLineRx Ltd. | 4.8 Million USD | -56.875% |
| Galectin Therapeutics Inc. | - USD | -Infinity% |
| Atai Life Sciences N.V. | 314 Thousand USD | -2298.089% |
| Aerovate Therapeutics, Inc. | - USD | -Infinity% |
| VistaGen Therapeutics, Inc. | 1.06 Million USD | -607.707% |
| Zentalis Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sagimet Biosciences Inc. | 2 Million USD | -276.5% |
| MediciNova, Inc. | 1 Million USD | -653.0% |
| Praxis Precision Medicines, Inc. | 2.44 Million USD | -207.724% |
| MiMedx Group, Inc. | 321.47 Million USD | 97.658% |
| Cardio Diagnostics Holdings, Inc. | 17.06 Thousand USD | -44025.403% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | 97.217% |
| PTC Therapeutics, Inc. | 937.82 Million USD | 99.197% |
| Mereo BioPharma Group plc | 10 Million USD | 24.7% |
| Syndax Pharmaceuticals, Inc. | - USD | -Infinity% |
| NRx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Dyne Therapeutics, Inc. | - USD | -Infinity% |
| BriaCell Therapeutics Corp. | - USD | -Infinity% |
| Allakos Inc. | - USD | -Infinity% |
| scPharmaceuticals Inc. | 13.59 Million USD | 44.604% |
| Fulcrum Therapeutics, Inc. | 2.8 Million USD | -168.449% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | 98.439% |
| NLS Pharmaceutics AG | - USD | -Infinity% |
| Precigen, Inc. | 6.22 Million USD | -20.964% |
| XOMA Corporation | 4.75 Million USD | -58.26% |
| Kezar Life Sciences, Inc. | 7 Million USD | -7.571% |
| Incyte Corporation | 3.69 Billion USD | 99.796% |
| Alzamend Neuro, Inc. | - USD | -Infinity% |
| Cara Therapeutics, Inc. | 20.96 Million USD | 64.088% |
| Aligos Therapeutics, Inc. | 15.52 Million USD | 51.51% |
| Seer, Inc. | 15.18 Million USD | 50.402% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| CRISPR Therapeutics AG | 371.2 Million USD | 97.971% |
| Akero Therapeutics, Inc. | - USD | -Infinity% |
| Eliem Therapeutics, Inc. | - USD | -Infinity% |
| EyeGate Pharmaceuticals, Inc. | 12.05 Thousand USD | -62342.989% |
| Akari Therapeutics, Plc | - USD | -Infinity% |
| Novavax, Inc. | 983.7 Million USD | 99.235% |
| Lexaria Bioscience Corp. | 226.2 Thousand USD | -3228.795% |
| UroGen Pharma Ltd. | 82.71 Million USD | 90.896% |
| Sutro Biopharma, Inc. | 153.73 Million USD | 95.102% |
| Entera Bio Ltd. | - USD | -Infinity% |
| Lisata Therapeutics, Inc. | - USD | -Infinity% |
| Stoke Therapeutics, Inc. | 8.78 Million USD | 14.237% |
| Chimerix, Inc. | 324 Thousand USD | -2224.074% |
| Reneo Pharmaceuticals, Inc. | - USD | -Infinity% |
| Phathom Pharmaceuticals, Inc. | 682 Thousand USD | -1004.106% |
| Outlook Therapeutics, Inc. | - USD | -Infinity% |
| Jazz Pharmaceuticals plc | 3.83 Billion USD | 99.804% |
| AnaptysBio, Inc. | 17.15 Million USD | 56.111% |
| Aprea Therapeutics, Inc. | 583.23 Thousand USD | -1191.084% |
| Portage Biotech Inc. | - USD | -Infinity% |
| Olema Pharmaceuticals, Inc. | - USD | -Infinity% |
| PMV Pharmaceuticals, Inc. | - USD | -Infinity% |
| OKYO Pharma Limited | - USD | -Infinity% |
| Qualigen Therapeutics, Inc. | 5.2 Million USD | -44.675% |
| Cadrenal Therapeutics, Inc. Common Stock | - USD | -Infinity% |
| Processa Pharmaceuticals, Inc. | - USD | -Infinity% |
| AbCellera Biologics Inc. | 38.02 Million USD | 80.197% |
| Genprex, Inc. | - USD | -Infinity% |
| Neumora Therapeutics, Inc. Common Stock | - USD | -Infinity% |
| NLS Pharmaceutics AG | - USD | -Infinity% |
| Virios Therapeutics, Inc. | - USD | -Infinity% |
| Daré Bioscience, Inc. | 2.8 Million USD | -168.173% |
| Titan Pharmaceuticals, Inc. | 184 Thousand USD | -3992.391% |
| Bicycle Therapeutics plc | 26.97 Million USD | 72.086% |
| Revolution Medicines, Inc. Warrant | 11.58 Million USD | 34.974% |
| Protagonist Therapeutics, Inc. | 60 Million USD | 87.45% |
| Erasca, Inc. | - USD | -Infinity% |
| bluebird bio, Inc. | 29.49 Million USD | 74.472% |
| Pieris Pharmaceuticals, Inc. | 42.81 Million USD | 82.411% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | 99.689% |
| DBV Technologies S.A. | 15.72 Million USD | 52.124% |
| Fortress Biotech, Inc. | 84.51 Million USD | 91.09% |
| Avidity Biosciences, Inc. | 9.56 Million USD | 21.234% |
| CorMedix Inc. | - USD | -Infinity% |
| Travere Therapeutics, Inc. | 145.23 Million USD | 94.815% |
| Sensei Biotherapeutics, Inc. | - USD | -Infinity% |
| Orchestra BioMed Holdings, Inc. | 2.76 Million USD | -172.826% |
| Spruce Biosciences, Inc. | 10.08 Million USD | 25.364% |
| Celldex Therapeutics, Inc. | 6.88 Million USD | -9.4% |
| Cartesian Therapeutics, Inc. | 26 Million USD | 71.043% |
| Cogent Biosciences, Inc. | - USD | -Infinity% |
| Onconetix, Inc. | 58.46 Thousand USD | -12779.501% |
| Ocuphire Pharma, Inc. | 19.04 Million USD | 60.47% |
| Prime Medicine, Inc. | - USD | -Infinity% |
| Adagene Inc. | 18.11 Million USD | 58.424% |
| Inhibrx Biosciences, Inc. | 1.8 Million USD | -318.333% |
| GlycoMimetics, Inc. | 10 Thousand USD | -75200.0% |
| Maravai LifeSciences Holdings, Inc. | 288.94 Million USD | 97.394% |
| Verve Therapeutics, Inc. | 11.75 Million USD | 35.958% |
| Voyager Therapeutics, Inc. | 250 Million USD | 96.988% |
| SciSparc Ltd. | 2.87 Million USD | -161.549% |
| Revelation Biosciences, Inc. | - USD | -Infinity% |
| Minerva Neurosciences, Inc. | - USD | -Infinity% |
| Astria Therapeutics, Inc. | - USD | -Infinity% |
| Spero Therapeutics, Inc. | 96.73 Million USD | 92.216% |
| Tevogen Bio Holdings Inc. | - USD | -Infinity% |
| Arcutis Biotherapeutics, Inc. | 59.6 Million USD | 87.367% |
| Marker Therapeutics, Inc. | 3.31 Million USD | -127.415% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | 99.588% |
| Artelo Biosciences, Inc. | - USD | -Infinity% |
| 2seventy bio, Inc. | 100.38 Million USD | 92.499% |
| ADMA Biologics, Inc. | 258.21 Million USD | 97.084% |
| Clene Inc. | 654 Thousand USD | -1051.376% |
| Capricor Therapeutics, Inc. | 25.17 Million USD | 70.093% |
| Boundless Bio, Inc. Common Stock | - USD | -Infinity% |
| Recursion Pharmaceuticals, Inc. | 44.57 Million USD | 83.107% |
| Citius Pharmaceuticals, Inc. | - USD | -Infinity% |
| Contineum Therapeutics, Inc. Class A Common Stock | 50 Million USD | 84.94% |
| Absci Corporation | 5.71 Million USD | -31.689% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 99.943% |
| Surrozen, Inc. | - USD | -Infinity% |
| Caribou Biosciences, Inc. | 34.47 Million USD | 78.159% |
| Janux Therapeutics, Inc. | 8.08 Million USD | 6.842% |
| Cingulate Inc. | - USD | -Infinity% |
| Galmed Pharmaceuticals Ltd. | - USD | -Infinity% |
| Tenax Therapeutics, Inc. | - USD | -Infinity% |
| Jaguar Health, Inc. | 9.76 Million USD | 22.856% |
| Terns Pharmaceuticals, Inc. | - USD | -Infinity% |
| ACADIA Pharmaceuticals Inc. | 726.43 Million USD | 98.963% |
| Kronos Bio, Inc. | 6.28 Million USD | -19.752% |
| Innoviva, Inc. | 310.46 Million USD | 97.575% |
| Bolt Biotherapeutics, Inc. | 7.87 Million USD | 4.393% |
| Entrada Therapeutics, Inc. | 129.01 Million USD | 94.163% |
| ZyVersa Therapeutics, Inc. | - USD | -Infinity% |
| Soligenix, Inc. | 839.35 Thousand USD | -797.113% |
| AlloVir, Inc. | - USD | -Infinity% |
| Century Therapeutics, Inc. | 2.23 Million USD | -236.913% |
| ORIC Pharmaceuticals, Inc. | - USD | -Infinity% |
| Kura Oncology, Inc. | - USD | -Infinity% |
| Ocean Biomedical, Inc. | - USD | -Infinity% |
| Mineralys Therapeutics, Inc. | - USD | -Infinity% |
| Eterna Therapeutics Inc. | 68 Thousand USD | -10973.529% |
| SELLAS Life Sciences Group, Inc. | - USD | -Infinity% |
| Heron Therapeutics, Inc. | 127.04 Million USD | 94.073% |
| SAB Biotherapeutics, Inc. | 2.23 Million USD | -236.312% |
| Pasithea Therapeutics Corp. | - USD | -Infinity% |
| Entero Therapeutics, Inc. | - USD | -Infinity% |
| HCW Biologics Inc. | 2.84 Million USD | -164.973% |
| C4 Therapeutics, Inc. | 20.75 Million USD | 63.721% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | 12.166% |
| Coherus BioSciences, Inc. | 257.24 Million USD | 97.073% |
| Lantern Pharma Inc. | - USD | -Infinity% |
| Histogen Inc. | 3.76 Million USD | -99.788% |
| Surrozen, Inc. | - USD | -Infinity% |
| Eledon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Kodiak Sciences Inc. | - USD | -Infinity% |
| MoonLake Immunotherapeutics | - USD | -Infinity% |
| Hepion Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adverum Biotechnologies, Inc. | 3.6 Million USD | -109.167% |
| Avalo Therapeutics, Inc. | 1.92 Million USD | -291.372% |
| Moderna, Inc. | 6.84 Billion USD | 99.89% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | 99.044% |
| Turnstone Biologics Corp. | 19.3 Million USD | 60.997% |
| Immix Biopharma, Inc. | - USD | -Infinity% |
| Tiziana Life Sciences Ltd | - USD | -Infinity% |
| Aurinia Pharmaceuticals Inc. | 175.51 Million USD | 95.71% |
| Exelixis, Inc. | 1.83 Billion USD | 99.589% |
| Monte Rosa Therapeutics, Inc. | - USD | -Infinity% |
| Wave Life Sciences Ltd. | 113.3 Million USD | 93.354% |
| Conduit Pharmaceuticals Inc. | - USD | -Infinity% |
| Alkermes plc | 1.66 Billion USD | 99.547% |
| Jasper Therapeutics, Inc. | - USD | -Infinity% |
| Arcellx, Inc. | 110.31 Million USD | 93.174% |
| ESSA Pharma Inc. | - USD | -Infinity% |
| TNF Pharmaceuticals, Inc. | - USD | -Infinity% |
| Avid Bioservices, Inc. | 139.91 Million USD | 94.618% |
| Insmed Incorporated | 305.2 Million USD | 97.533% |
| Cardiff Oncology, Inc. | 488 Thousand USD | -1443.033% |
| Enanta Pharmaceuticals, Inc. | 79.2 Million USD | 90.493% |
| Moolec Science SA | 905.04 Thousand USD | -731.999% |
| RenovoRx, Inc. | - USD | -Infinity% |
| Acumen Pharmaceuticals, Inc. | - USD | -Infinity% |
| Geron Corporation | 237 Thousand USD | -3077.215% |
| LAVA Therapeutics N.V. | 6.76 Million USD | -11.242% |
| Verrica Pharmaceuticals Inc. | 5.12 Million USD | -46.956% |
| Royalty Pharma plc | 2.35 Billion USD | 99.68% |
| OmniAb, Inc. | 34.16 Million USD | 77.959% |
| Alector, Inc. | 97.06 Million USD | 92.242% |
| Atea Pharmaceuticals, Inc. | - USD | -Infinity% |
| Mersana Therapeutics, Inc. | 36.85 Million USD | 79.569% |
| Humacyte, Inc. | - USD | -Infinity% |
| Structure Therapeutics Inc. | - USD | -Infinity% |
| Revance Therapeutics, Inc. | 234.04 Million USD | 96.783% |
| 89bio, Inc. | - USD | -Infinity% |
| Avenue Therapeutics, Inc. | - USD | -Infinity% |
| Aura Biosciences, Inc. | - USD | -Infinity% |
| Immunic, Inc. | - USD | -Infinity% |
| Veracyte, Inc. | 361.05 Million USD | 97.914% |
| Genelux Corporation | 170 Thousand USD | -4329.412% |
| Trevi Therapeutics, Inc. | - USD | -Infinity% |
| Adial Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sonnet BioTherapeutics Holdings, Inc. | 147.8 Thousand USD | -4994.55% |
| Immunovant, Inc. | - USD | -Infinity% |
| Vericel Corporation | 197.51 Million USD | 96.188% |
| Fortrea Holdings Inc. | 3.1 Billion USD | 99.758% |
| KalVista Pharmaceuticals, Inc. | - USD | -Infinity% |
| XBiotech Inc. | - USD | -Infinity% |
| Agenus Inc. | 156.31 Million USD | 95.183% |
| Acasti Pharma Inc. | - USD | -Infinity% |
| Kiora Pharmaceuticals, Inc. | - USD | -Infinity% |
| MiNK Therapeutics, Inc. | - USD | -Infinity% |
| Pasithea Therapeutics Corp. | - USD | -Infinity% |
| Theravance Biopharma, Inc. | 57.42 Million USD | 86.887% |
| Metagenomi, Inc. Common Stock | 44.75 Million USD | 83.175% |
| NeuroBo Pharmaceuticals, Inc. | - USD | -Infinity% |
| Gain Therapeutics, Inc. | 55.18 Thousand USD | -13546.249% |
| Tempest Therapeutics, Inc. | - USD | -Infinity% |
| Sol-Gel Technologies Ltd. | 1.55 Million USD | -384.556% |
| Rhythm Pharmaceuticals, Inc. | 77.42 Million USD | 90.275% |
| United Therapeutics Corporation | 2.32 Billion USD | 99.676% |
| Creative Medical Technology Holdings, Inc. | 9000.00 USD | -83566.667% |
| BriaCell Therapeutics Corp. | - USD | -Infinity% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| Silo Pharma, Inc. | 72.1 Thousand USD | -10343.538% |
| Telomir Pharmaceuticals, Inc. Common Stock | - USD | -Infinity% |
| Pharming Group N.V. | 245.31 Million USD | 96.93% |
| XOMA Corporation | 4.75 Million USD | -58.26% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Bionomics Limited | - USD | -Infinity% |
| Alpha Tau Medical Ltd. | - USD | -Infinity% |
| Pyxis Oncology, Inc. | - USD | -Infinity% |
| uniQure N.V. | 15.84 Million USD | 52.471% |
| Xilio Therapeutics, Inc. | - USD | -Infinity% |
| Cassava Sciences, Inc. | - USD | -Infinity% |
| 60 Degrees Pharmaceuticals, Inc. | 253.57 Thousand USD | -2869.559% |
| Windtree Therapeutics, Inc. | - USD | -Infinity% |
| Poseida Therapeutics, Inc. | 64.7 Million USD | 88.362% |
| Pluri Inc. | 326 Thousand USD | -2209.816% |
| Anebulo Pharmaceuticals, Inc. | - USD | -Infinity% |
| MeiraGTx Holdings plc | 14.01 Million USD | 46.28% |
| Cidara Therapeutics, Inc. | 63.9 Million USD | 88.217% |
| ProMIS Neurosciences, Inc. | - USD | -Infinity% |
| CalciMedica, Inc. | - USD | -Infinity% |
| Sana Biotechnology, Inc. | - USD | -Infinity% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | 98.114% |
| Salarius Pharmaceuticals, Inc. | - USD | -Infinity% |
| Alpha Tau Medical Ltd. | - USD | -Infinity% |
| Adlai Nortye Ltd. American Depositary Shares | 4.99 Million USD | -50.731% |
| Nutriband Inc. | 2.08 Million USD | -261.097% |
| Protara Therapeutics, Inc. | - USD | -Infinity% |
| Compugen Ltd. | 33.45 Million USD | 77.495% |
| Roivant Sciences Ltd. | 124.79 Million USD | 93.966% |
| ProKidney Corp. | - USD | -Infinity% |
| Protagenic Therapeutics, Inc. | - USD | -Infinity% |
| Elevai Labs, Inc. Common Stock | 1.71 Million USD | -339.684% |
| Tango Therapeutics, Inc. | 36.52 Million USD | 79.385% |
| Renovaro Biosciences Inc. | - USD | -Infinity% |
| Zevra Therapeutics, Inc. | 27.46 Million USD | 72.579% |
| Benitec Biopharma Inc. | 216 Thousand USD | -3386.111% |
| GeoVax Labs, Inc. | - USD | -Infinity% |
| Biomea Fusion, Inc. | - USD | -Infinity% |
| Cullinan Oncology, Inc. | - USD | -Infinity% |
| 4D Molecular Therapeutics, Inc. | 20.72 Million USD | 63.664% |
| Kiniksa Pharmaceuticals, Ltd. | 270.25 Million USD | 97.214% |
| Nuvectis Pharma, Inc. | - USD | -Infinity% |
| Spyre Therapeutics, Inc. | 886 Thousand USD | -749.887% |
| Ventyx Biosciences, Inc. | - USD | -Infinity% |
| Imunon, Inc. | - USD | -Infinity% |
| BioAtla, Inc. | - USD | -Infinity% |
| Allogene Therapeutics, Inc. | 95 Thousand USD | -7826.316% |
| Larimar Therapeutics, Inc. | - USD | -Infinity% |
| Zura Bio Limited | - USD | -Infinity% |
| aTyr Pharma, Inc. | 353 Thousand USD | -2033.144% |
| Madrigal Pharmaceuticals, Inc. | - USD | -Infinity% |
| Viridian Therapeutics, Inc. | 314 Thousand USD | -2298.089% |
| Galecto, Inc. | - USD | -Infinity% |
| Tevogen Bio Holdings Inc. | - USD | -Infinity% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | 99.092% |
| Lexicon Pharmaceuticals, Inc. | 1.2 Million USD | -525.415% |
| PolyPid Ltd. | - USD | -Infinity% |
| Aileron Therapeutics, Inc. | - USD | -Infinity% |
| Forte Biosciences, Inc. | - USD | -Infinity% |
| Xencor, Inc. | 168.33 Million USD | 95.527% |
| Coeptis Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Lexaria Bioscience Corp. | 226.2 Thousand USD | -3228.795% |
| Instil Bio, Inc. | - USD | -Infinity% |
| Cardio Diagnostics Holdings, Inc. | 17.06 Thousand USD | -44025.403% |
| OncoCyte Corporation | 1.5 Million USD | -400.998% |
| Elevation Oncology, Inc. | - USD | -Infinity% |
| Purple Biotech Ltd. | - USD | -Infinity% |
| CollPlant Biotechnologies Ltd. | 10.95 Million USD | 31.289% |
| MacroGenics, Inc. | 58.74 Million USD | 87.183% |
| Verona Pharma plc | - USD | -Infinity% |
| Tharimmune, Inc. | - USD | -Infinity% |
| Apogee Therapeutics, Inc. | - USD | -Infinity% |
| enGene Holdings Inc. Warrants | - USD | -Infinity% |
| Aditxt, Inc. | 645.17 Thousand USD | -1067.123% |
| XTL Biopharmaceuticals Ltd. | - USD | -Infinity% |
| Savara Inc. | - USD | -Infinity% |
| Curis, Inc. | 10.02 Million USD | 24.873% |
| Carmell Therapeutics Corporation | - USD | -Infinity% |
| Achieve Life Sciences, Inc. | - USD | -Infinity% |
| BeiGene, Ltd. | 2.45 Billion USD | 99.694% |
| Protagenic Therapeutics, Inc. | - USD | -Infinity% |
| Vincerx Pharma, Inc. | - USD | -Infinity% |
| Plus Therapeutics, Inc. | 4.91 Million USD | -53.267% |
| Acrivon Therapeutics, Inc. Common Stock | - USD | -Infinity% |
| Rigel Pharmaceuticals, Inc. | 116.88 Million USD | 93.558% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| Quantum-Si incorporated | 1.08 Million USD | -595.933% |
| Acurx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Generation Bio Co. | 5.9 Million USD | -27.541% |
| Black Diamond Therapeutics, Inc. | - USD | -Infinity% |
| Invivyd, Inc. | - USD | -Infinity% |
| Relay Therapeutics, Inc. | 25.54 Million USD | 70.524% |
| Quoin Pharmaceuticals, Ltd. | - USD | -Infinity% |
| Moolec Science SA | 905.04 Thousand USD | -731.999% |
| Clearside Biomedical, Inc. | 8.22 Million USD | 8.461% |
| Longboard Pharmaceuticals, Inc. | - USD | -Infinity% |
| Relmada Therapeutics, Inc. | - USD | -Infinity% |
| ALX Oncology Holdings Inc. | - USD | -Infinity% |
| Vir Biotechnology, Inc. | 86.18 Million USD | 91.262% |
| Evaxion Biotech A/S | 73.11 Thousand USD | -10199.267% |
| Ocular Therapeutix, Inc. | 58.44 Million USD | 87.116% |
| Tyra Biosciences, Inc. | - USD | -Infinity% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| Connect Biopharma Holdings Limited | - USD | -Infinity% |
| Clearmind Medicine Inc. | - USD | -Infinity% |
| Aadi Bioscience, Inc. | 24.35 Million USD | 69.081% |
| Catalyst Pharmaceuticals, Inc. | 398.2 Million USD | 98.109% |
| CERo Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Keros Therapeutics, Inc. | 151 Thousand USD | -4886.755% |
| Crinetics Pharmaceuticals, Inc. | 4.01 Million USD | -87.64% |
| ImmunityBio, Inc. | 622 Thousand USD | -1110.611% |
| Korro Bio, Inc. | - USD | -Infinity% |
| Kineta, Inc. | 5.44 Million USD | -38.368% |
| BioVie Inc. | - USD | -Infinity% |
| Codexis, Inc. | 70.14 Million USD | 89.265% |
| Celularity Inc. | 22.77 Million USD | 66.932% |
| Virax Biolabs Group Limited | 156.41 Thousand USD | -4713.993% |
| Cibus, Inc. | 1.81 Million USD | -314.419% |
| Annexon, Inc. | - USD | -Infinity% |
| Assembly Biosciences, Inc. | 7.16 Million USD | -5.124% |
| Eyenovia, Inc. | 3787.00 USD | -198738.13% |
| Puma Biotechnology, Inc. | 235.63 Million USD | 96.804% |
| NeurAxis, Inc. | 2.46 Million USD | -206.091% |
| Regulus Therapeutics Inc. | - USD | -Infinity% |
| Compass Therapeutics, Inc. | - USD | -Infinity% |
| TFF Pharmaceuticals, Inc. | 733.87 Thousand USD | -926.066% |
| Notable Labs, Ltd. | 310 Thousand USD | -2329.032% |
| IN8bio, Inc. | - USD | -Infinity% |
| DiaMedica Therapeutics Inc. | - USD | -Infinity% |
| Vera Therapeutics, Inc. | 1.86 Million USD | -304.404% |
| Lumos Pharma, Inc. | 2.05 Million USD | -267.138% |
| Liquidia Corporation | 17.48 Million USD | 56.942% |
| Mustang Bio, Inc. | - USD | -Infinity% |
| Quantum-Si incorporated | 1.08 Million USD | -595.933% |
| Arbutus Biopharma Corporation | 18.14 Million USD | 58.492% |
| enGene Holdings Inc. Common Stock | - USD | -Infinity% |
| ARS Pharmaceuticals, Inc. | 30 Thousand USD | -25000.0% |
| 180 Life Sciences Corp. | - USD | -Infinity% |
| Vaxcyte, Inc. | - USD | -Infinity% |
| Xenon Pharmaceuticals Inc. | - USD | -Infinity% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| NKGen Biotech, Inc. Warrants | - USD | -Infinity% |
| Opiant Pharmaceuticals, Inc. | 40.72 Million USD | 81.51% |
| CERo Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Soleno Therapeutics, Inc. | - USD | -Infinity% |
| PepGen Inc. | - USD | -Infinity% |
| Moleculin Biotech, Inc. | - USD | -Infinity% |
| Solid Biosciences Inc. | - USD | -Infinity% |
| Palisade Bio, Inc. | 250 Thousand USD | -2912.0% |
| Nutriband Inc. | 2.08 Million USD | -261.097% |
| Conduit Pharmaceuticals Inc. | - USD | -Infinity% |
| Immuneering Corporation | - USD | -Infinity% |
| Belite Bio, Inc | - USD | -Infinity% |
| CG Oncology, Inc. Common stock | 204 Thousand USD | -3591.176% |
| GeoVax Labs, Inc. | - USD | -Infinity% |
| Tourmaline Bio, Inc. | - USD | -Infinity% |
| Altimmune, Inc. | 426 Thousand USD | -1667.606% |
| Peak Bio, Inc. | 367.87 Thousand USD | -1946.88% |
| SeaStar Medical Holding Corporation | - USD | -Infinity% |
| FibroBiologics, Inc. Common Stock | - USD | -Infinity% |
| Neurogene Inc. | - USD | -Infinity% |
| Mirum Pharmaceuticals, Inc. | 186.37 Million USD | 95.96% |
| Kintara Therapeutics, Inc. | - USD | -Infinity% |
| CARGO Therapeutics, Inc. Common Stock | - USD | -Infinity% |
| Sesen Bio, Inc. | 40 Million USD | 81.175% |
| argenx SE | 1.22 Billion USD | 99.386% |
| NKGen Biotech, Inc. Common Stock | - USD | -Infinity% |
| Dianthus Therapeutics, Inc. | 2.82 Million USD | -166.454% |
| Immunome, Inc. | 14.01 Million USD | 46.283% |
| Enveric Biosciences, Inc. | - USD | -Infinity% |
| Design Therapeutics, Inc. | - USD | -Infinity% |
| Seelos Therapeutics, Inc. | 2.2 Million USD | -241.807% |
| Enliven Therapeutics, Inc. | - USD | -Infinity% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -533.305% |
| Taysha Gene Therapies, Inc. | 15.45 Million USD | 51.265% |
| Inovio Pharmaceuticals, Inc. | 832.01 Thousand USD | -805.037% |
| Athira Pharma, Inc. | - USD | -Infinity% |
| XOMA Corporation | 4.75 Million USD | -58.26% |
| Merus N.V. | 43.94 Million USD | 82.866% |
| Quince Therapeutics, Inc. | - USD | -Infinity% |
| Rezolute, Inc. | - USD | -Infinity% |
| Clene Inc. | 654 Thousand USD | -1051.376% |
| Indaptus Therapeutics, Inc. | - USD | -Infinity% |
| BeyondSpring Inc. | 1.75 Million USD | -330.04% |
| Synlogic, Inc. | 3.37 Million USD | -123.376% |
| Allarity Therapeutics, Inc. | - USD | -Infinity% |
| Phio Pharmaceuticals Corp. | - USD | -Infinity% |
| Peak Bio, Inc. | 367.87 Thousand USD | -1946.88% |
| Werewolf Therapeutics, Inc. | 19.94 Million USD | 62.242% |
| Krystal Biotech, Inc. | 50.69 Million USD | 85.148% |
| Karyopharm Therapeutics Inc. | 146.03 Million USD | 94.844% |
| SpringWorks Therapeutics, Inc. | 5.44 Million USD | -38.241% |
| Lipella Pharmaceuticals Inc. | 449.61 Thousand USD | -1574.759% |
| MannKind Corporation | 198.96 Million USD | 96.215% |
| Ikena Oncology, Inc. | 9.16 Million USD | 17.795% |
| Cyclerion Therapeutics, Inc. | - USD | -Infinity% |
| Gyre Therapeutics, Inc. | 113.45 Million USD | 93.363% |
| Gossamer Bio, Inc. | - USD | -Infinity% |
| CohBar, Inc. | - USD | -Infinity% |
| Cognition Therapeutics, Inc. | - USD | -Infinity% |
| NRx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Legend Biotech Corporation | 285.14 Million USD | 97.359% |
| Mural Oncology plc | - USD | -Infinity% |
| Disc Medicine, Inc. | - USD | -Infinity% |
| Champions Oncology, Inc. | 50.15 Million USD | 84.987% |
| REGENXBIO Inc. | 90.24 Million USD | 91.656% |
| Ensysce Biosciences, Inc. | 2.23 Million USD | -237.589% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Cellectar Biosciences, Inc. | - USD | -Infinity% |
| Edgewise Therapeutics, Inc. | - USD | -Infinity% |
| Vaxart, Inc. | 7.37 Million USD | -2.046% |
| PharmaCyte Biotech, Inc. | - USD | -Infinity% |
| Aldeyra Therapeutics, Inc. | - USD | -Infinity% |
| Cellectis S.A. | 755 Thousand USD | -897.351% |
| Longeveron Inc. | 709 Thousand USD | -962.059% |
| Repare Therapeutics Inc. | 51.13 Million USD | 85.274% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | 99.394% |
| Inozyme Pharma, Inc. | - USD | -Infinity% |
| Revolution Medicines, Inc. | 11.58 Million USD | 34.974% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| Third Harmonic Bio, Inc. | - USD | -Infinity% |
| ArriVent BioPharma, Inc. Common Stock | - USD | -Infinity% |
| AN2 Therapeutics, Inc. | - USD | -Infinity% |
| Anixa Biosciences, Inc. | 210 Thousand USD | -3485.714% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 99.924% |
| Denali Therapeutics Inc. | 330.53 Million USD | 97.722% |
| Revelation Biosciences, Inc. | - USD | -Infinity% |
| Veru Inc. | 16.29 Million USD | 53.795% |
| Corvus Pharmaceuticals, Inc. | - USD | -Infinity% |
| Cingulate Inc. | - USD | -Infinity% |
| Passage Bio, Inc. | - USD | -Infinity% |
| Context Therapeutics Inc. | - USD | -Infinity% |
| Exicure, Inc. | - USD | -Infinity% |
| Day One Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Oramed Pharmaceuticals Inc. | 2.7 Million USD | -178.579% |
| Scinai Immunotherapeutics Ltd. | - USD | -Infinity% |
| Nuvalent, Inc. | - USD | -Infinity% |
| ABVC BioPharma, Inc. | 152.43 Thousand USD | -4839.972% |
| Carisma Therapeutics, Inc. | 14.91 Million USD | 49.527% |
| Unicycive Therapeutics, Inc. | 675 Thousand USD | -1015.556% |
| OmniAb, Inc. | 34.16 Million USD | 77.959% |
| Anew Medical, Inc. | - USD | -Infinity% |
| Fennec Pharmaceuticals Inc. | 21.25 Million USD | 64.568% |
| Lipocine Inc. | -2.85 Million USD | 364.135% |
| Lexeo Therapeutics, Inc. Common Stock | - USD | -Infinity% |
| Nautilus Biotechnology, Inc. | - USD | -Infinity% |
| SAB Biotherapeutics, Inc. | 2.23 Million USD | -236.312% |
| G1 Therapeutics, Inc. | 82.51 Million USD | 90.874% |
| Bellerophon Therapeutics, Inc. | - USD | -Infinity% |
| Sage Therapeutics, Inc. | 86.45 Million USD | 91.29% |
| Ocugen, Inc. | 6.03 Million USD | -24.751% |
| Mind Medicine (MindMed) Inc. | - USD | -Infinity% |
| Q32 Bio Inc. | 1.15 Million USD | -551.384% |
| Brainstorm Cell Therapeutics Inc. | - USD | -Infinity% |
| Alumis Inc. Common Stock | - USD | -Infinity% |
| Equillium, Inc. | 36.08 Million USD | 79.132% |
| Kyverna Therapeutics, Inc. | - USD | -Infinity% |
| Coya Therapeutics, Inc. | 6 Million USD | -25.454% |
| CNS Pharmaceuticals, Inc. | - USD | -Infinity% |
| Dominari Holdings Inc. | 2.03 Million USD | -269.299% |
| Edesa Biotech, Inc. | - USD | -Infinity% |
| vTv Therapeutics Inc. | - USD | -Infinity% |
| Bio-Techne Corporation | 1.15 Billion USD | 99.35% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | 71.927% |
| Harmony Biosciences Holdings, Inc. | 582.02 Million USD | 98.706% |
| Prelude Therapeutics Incorporated | - USD | -Infinity% |
| Candel Therapeutics, Inc. | - USD | -Infinity% |
| iTeos Therapeutics, Inc. | 12.59 Million USD | 40.214% |
| Nkarta, Inc. | - USD | -Infinity% |
| BioCardia, Inc. | 477 Thousand USD | -1478.616% |
| Iterum Therapeutics plc | - USD | -Infinity% |